Answers are grounded in this paper and cite their sources.
Gunnarsson, R., and Wilton, P. (Medical Department, KabiVitrum Peptide Hormones, Stockholm, Sweden). Clinical experience with Genotropin worldwide: an update March 1987. Acta Paediatr Scand [Suppl] 337:147, 1987. The efficacy and safety of Genotropin (recombinant somatropin, KabiVitrum AB, Sweden) was analysed in 199 children with hGH deficiency, comprising a combined series of four current multicentre trials. Stimulation of linear growth from pretreatment height velocities of 3–4 cm/year to about 10 cm/year was observed after 6 and 9 months of treatment. Statistical analysis revealed significantly greater height velocities (by 2–3 cm/year) when the weekly dose of the hormone was given in 6–7 injections rather than in 3 injections. Immunogenicity seems to be very low, with only about 2% of the children having detectable antibodies during treatment.
No takes yet. Share an insight, caveat, or question.
Gunnarsson et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: